BASEL, Switzerland -- Roche has expanded its exclusive distribution agreement with Senseonics Holdings, Inc. Under the terms of the agreement, Roche will have exclusive rights to promote, market and sell the implantable Eversense CGM system across Europe, Middle East and Africa, excluding Scandinavia and Israel, while Senseonics will retain responsibility for product development, regulatory approval, quality management, and manufacturing.
The system will be made available to people with diabetes via clinics and medical practices that have been trained on the system. In May of this year, Roche had already signed an exclusive distribution agreement with Senseonics for its three pilot markets Germany, Italy and the Netherlands.
For more information, visit:
http://www.senseonics.com
http://www.roche.com
http://www.accu-chek.com